DioTree is passionately dedicated to developing innovative treatment for high grade serous ovarian cancer (HGSOC), one of the deadliest human cancers with an extremely poor prognosis.

Aug 10, 2023 · Dio Tree has raised $400,000 for its efforts to treat ovarian cancer - something that affects 300,000 women globally each year. “The backdrop of cancer treatment, especially …

Dio-Tree is pioneering a breakthrough solution targeting the DIO3 enzyme, with the goal of developing a revolutionary treatment for ovarian cancer. BIO-Europe is the perfect platform to connect...

DioTree develops technology for treatment of high grade serous ovarian cancer (HGSOC). A novel technology targeting the DIO3 enzyme to inhibit its function, potentially treating various aggressive cancers including ovarian cancer.

Operator of a pharmaceutical company intended to develop a new mechanism of action and novel small molecule technology for curing ovarian cancer.

Aug 10, 2023 · Dio Tree develops a novel small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, which is a major driver in many types of cancer, specifically ovarian cancer.

Dio Tree develops a novel, first in class, small molecule for the treatment of ovarian cancer. The new technology is based on inhibition of the enzyme DIO3, which is a major driver in many types of cancer, and specifically, in ovarian cancer.

Dio Tree focuses on cancer treatment, specifically targeting high-grade serous ovarian cancer (HGSOC) within the biotechnology and pharmaceutical industry. The company develops novel small molecule technology aimed at inhibiting the DIO3 enzyme, which is implicated in the progression of ovarian cancer and other aggressive tumors.

Our mission is to develop novel treatment for high grade serous ovarian cancer (HGSOC) using our innovative small molecule technology targeting the enzyme DIO3🌳🔬 We cordially invite you to...

Apr 13, 2023 · Dio Tree is developing first-in-class small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, a major driver in many types of cancer, specifically, ovarian cancer.